Avanza Bank Holding AB: 1 director

A director at Avanza Bank Holding AB bought 1,500 shares at 313.130SEK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

Heads-up for report 25 April

Tryg AS: 2 directors

Two Directors at Tryg AS sold 65,000 shares at between 149.720DKK and 149.964DKK. The significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...

Nordic Semiconductor (Buy, TP: NOK174.00) - Near-term momentum likely ...

While the effects of trade tensions and tariff upheaval remain uncertain, our discussions with industry sources suggest strong, improving order momentum in Q1. Moreover, we expect the recently announced 90-day tariff pause to drive pull-forward of US imports. This has led us to shift our estimates from H2 towards H1. Beyond tariff-induced pull-ins, Dexcom channel replenishment dynamics remain one company-specific source of uncertainty to watch, while we estimate a limited effect. We remain sligh...

Coloplast (Hold, TP: DKK770.00) - Expecting another weak quarter

We expect another soft quarter (7.8% organic revenue growth YOY and a 27.5% EBIT margin), before then improving. We look for unchanged 2024/25 guidance of 8–9% organic sales growth and a c28% EBIT margin before special items. We have cut our 2024/25–2026/27e EPS by 2.8% on average and believe returning to a 30%+ EBIT margin hinges on external factors. We reiterate our HOLD, but have cut our target price to DKK770 (850).

The Capital Goods Data Miner - April 2025

Tryg (Buy, TP: DKK185.00) - Earnings momentum still solid

Through both favourable weather and narrowing credit spreads, Q1 PTP was 48% higher YOY. Recent repricing efforts continue to take effect, as seen in a 0.3%-points improved underlying claims ratio YOY, although portfolio rebalancing weighed somewhat on growth. Supported by an outlook for abating motor claims pressure, we continue to find the investment case favourable. Having made limited EPS revisions for 2026–2027e, we reiterate our BUY and DKK185 target price.

A safer place to be

PTP beat from financials, UW inline

PTP beat from better financials, UW inline or a tad better. Reiterate '27 guidance and '25 premium growth from private/SMEs. Stock to outperform 1-3%; cons.est.rev. minor; strong read-x to GJF

Heads-up for Q1-report, 11 April

Nordic non-life Q1e: Should manage the turmoil

Efficient and with lower risk

Q1 was OK but that's ancient history now

Tariff risk, but also B/S potential, better value

Wärtsilä (Buy, TP: EUR20.00) - Setbacks in Energy

Based on recent news flow relating to Energy and FX, we have cut our 2025–2027e clean EPS by 5% on average and our target price to EUR20 (22). We reiterate our BUY and continue to highlight Wärtsilä’s solid earnings quality and attractive valuation. The Q1 results are due on 25 April (no details available). Our forecast orders and clean EBIT are below post-Q4 consensus.

Solid growth momentum into 2025e

Helped by benign weather with few storms, we expect solid underwriting across the Nordic P&C sector for Q1, with underlying performance further supported by earned repricing momentum and abating claims inflation. The sector is trading at an attractive average 2026e P/E of c15.2x and we see solid capital distribution prospects. We reiterate our recommendations on all our covered sector names and highlight Tryg as our top pick.

Non-life: Competition authority consider to look at the competition

The DCCA is out with report describing inefficient comp. Could be a drag for Tryg and ALMB despite the industry objections. ALMB drop looks attractive, but it could drag on for two more years.

Storage still in

Two birds with one (very tiny) stone